Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)

Publication

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)

Keune, Philipp M.; Cocks, Adam J.; Young, William R.; u. a. (2025): Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine), in: Bamberg: Otto-Friedrich-Universität, S. 1–8.

Details

Faculty/Chair
Faculty/Professorship
Author
Keune, Philipp M.
Cocks, Adam J.
Young, William R.
Burschka, Janina M.
Hansen, Sascha
Hofstadt-van Oy, Ulrich
Oschmann, Patrick
Muenssinger, Jana
Publisher Information
Otto-Friedrich-Universität : Bamberg
Year of publication
2025
Source/Other editions
BMC Neurology, London: Springer Science and Business Media LLC (2015), Vol. 15, Nr. 1, pp. 1–8, ISSN: 1471-2377
Year of first publication
2015
Language
English
Licence
URN
Abstract

Background

Impaired walking capacity is a frequent confinement in Multiple Sclerosis (MS). Patients are affected by limitations in coordination, walking speed and the distance they may cover. Also abnormal dynamic walking patterns have been reported, involving continuous deceleration over time. Fampridine (4-aminopyridine), a potassium channel blocker, may improve walking in MS. The objective of the current study was to comprehensively examine dynamic walking characteristics and improved walking capacity in MS patients treated with fampridine.

Methods

A sample of N = 35 MS patients (EDSS median: 4) underwent an electronic walking examination prior to (Time 1), and during treatment with fampridine (Time 2). Patients walked back and forth a distance of 25 ft for a maximum period of 6 min (6-minute 25-foot-walk). Besides the total distance covered, average speed on the 25-foot distance and on turns was determined separately for each test minute, at Time 1 and Time 2.

Results

Prior to fampridine administration, 27/35 patients (77 %) were able to complete the entire 6 min of walking, while following the administration, 34/35 patients (97 %) managed to walk for 6 min. In this context, walking distance considerably increased and treatment was associated with faster walking and turning across all six test minutes (range of effect sizes: partial eta squared = .34-.72). Importantly, previously reported deceleration across test minutes was consistently observable at Time 1 and Time 2.

Discussion

Fampridine administration is associated with improved walking speed and endurance. Regardless of a treatment effect of fampridine, the previously identified, abnormal dynamic walking feature, i.e. the linear decline in walking speed, may represent a robust feature.

Conclusions

The dynamic walking feature might hence be considered as a candidate for a new outcome measure in clinical studies involving interventions other than symptomatic treatment, such as immune-modulating medication.

Trial registration

GND Keywords
Multiple Sklerose
Gehen
Keywords
Multiple sclerosis (MS)
Fampridine
4-aminopyridine
Walking capacity
Walking dynamics
Linear deceleration
6-minute walk
25-foot-walk
DDC Classification
150 Psychology
RVK Classification
CZ 1380
Type
Article
URI
Activation date
2025-08-07

Permalink: https://fis.uni-bamberg.de/handle/uniba/109430 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-16

Restricted read-only access: login, editing and submission are temporarily disabled.